1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kohjin Bio Co., Ltd.

Kohjin Bio Co., Ltd.

177A.T
Kohjin Bio Co., Ltd.JP flagTokyo Stock Exchange
1,016.00
JPY
+15.00
- -
5.19BMarket Cap
Kohjin Bio Co., Ltd.
177A.T
(Tokyo Stock Exchange)

Recent

price

1,016.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
FRC
787.06
1,138.77
1,145.28
1,032.17
253.19
Revenue per Share
117.18
199.23
92.43
157.56
36.74
Basic EPS, GAAP
111.55
-23.91
62.64
5.56
- -
Free Cash Flow per Basic Share
6.75
10
19
11.56
- -
Dividend per Share
371.14
636.12
709.55
895.92
826.69
Book Value per Share
440.86
723.52
801.78
1,140.87
1,086.47
Tangible Book Value per Share
5
4
4
5
5
Basic Weighted Avg Shares
3,947
4,743
4,770
5,206
1,226
Sales/Revenue/Turnover
24.56
26.72
12.51
19.04
18.43
Operating Margin (%)
179
168
300
361
- -
Depreciation Expense
588
830
385
795
178
Net Income, GAAP
36.27
33.31
39.43
21.72
25.2
Effective Tax Rate (%)
14.89
17.5
8.07
15.27
14.51
Profit Margin (%)
1,236
457
1,012
2,580
2,479
Working Capital
1,099
15
767
685
450
LT Debt
2,217
3,018
3,342
5,782
5,279
Total Equity
- -
16.79
6.43
10.96
- -
Return on Invested Capital (%)
- -
19.26
7.84
13.27
- -
Return on Capital (%)
- -
36.79
13.74
21.27
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
ST Debt
1,650
LT Borrowings
450
LT Finance Leases
- -
Preferred Equity and Hybrid Capital
- -
Shares Outstanding
5
Market Capitalization
8,837

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Total Current Assets
4,925
Cash, Cash Equivalents & STI
3,307
Accounts Receivable, Net
701
Inventories
685
Total Current Liabilities
2,445
Payables & Accruals
- -
ST Debt
1,650
Deferred Revenue
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
72.98%
Free Cash Flow
- -
- -
-89.25%
Net Income, GAAP
- -
- -
106.44%
Sales/Revenue/Turnover
- -
- -
9.14%
Total Cash Common Dividend
- -
- -
-26.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1,226
- -
- -
4,770
2025
- -
- -
- -
- -
5,206
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
92.43
2025
- -
- -
- -
- -
157.56
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
19
2025
- -
- -
- -
- -
11.56
2026
- -
- -
- -
- -
- -
Similar Companies
Acer Therapeutics Inc. (ACER)
NovaBay Pharmaceuticals, Inc. (NBY)
Medicus Pharma Ltd. Common Stock (MDCX)
Newron Pharmaceuticals S.p.A. (NWRN.SW)
Mesoblast Limited (MEOBF)
OPKO Health, Inc. (OPK.TA)
Business
Kohjin Bio Co., Ltd. Kohjin Bio Co., Ltd. (177A.T) manufactures and sells biotechnology products including animal blood and sera; tissue culture media such as serum-free media for regenerative medicine, immunotherapy research, virus and recombinant protein production, hybridoma, human lymphocyte culture, insect cell lines, normal human cells, ES cells, in-vitro fertilization and early embryo culture kits, supplements, cell separation solutions, physiological salt solutions, and research reagents; microbial testing products comprising agar media for microorganism tests like sheep blood agar, GC chocolate agar, gram positive cocci, gram negative bacteria, susceptibility testing, differential, anaerobic growth, fungal, tube, food-related sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, vibrio parahaemolyticus, total viable cell count, campylobacter mediums; in-vitro diagnostic agents; cosmetics; laboratory animals; and medical equipment, with services encompassing animal immunization, antibody preparation, import/export operations, and contract cell processing for cancer immune cell therapy under the Regenerative Medicine Safety Act. The company, founded in 1981 and headquartered in Sakado-shi, Saitama, Japan, maintains branches in Tokyo, Nagoya, Osaka, and Fukuoka, with consolidated subsidiaries including En Bio’s Co., Ltd. in Tokyo, Kohjin-Bio Technology (Shanghai) Co., Ltd. in China, Kohjin Bio Holding (Hong Kong) Limited, and Ajinomoto Kohjin Bio Co., Ltd., a joint venture established in 2018 with Ajinomoto Co., Inc. to produce clinical-grade cell culture media. Recent developments include a 2024 contract with OrganTech for technology transfer and patent licensing related to artificial skin technology for organ regeneration research support; revenue growth to 5.21 billion yen in fiscal 2024, up 9.14% year-over-year; and ongoing expansion in regenerative medicine cell processing and biotechnology supply capabilities.